ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Merck buys immunotherapy-focused Tilos

by Lisa M. Jarvis
June 15, 2019 | APPEARED IN VOLUME 97, ISSUE 24

 

Merck & Co. is expanding its immunotherapy portfolio with the purchase of Tilos Therapeutics. The deal, worth up to $773 million, gives Merck a stable of cancer therapies aimed at modulating the activity of TGFβ, a cytokine that helps dampen the immune system response. Cambridge, Massachusetts–based Tilos has developed antibodies that act on latentcy-associated peptide, a protein that envelops TGFβ. The strategy both prevents the release of TGFβ and targets certain key cells for deletion from the tumor microenvironment.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment